https://www.selleckchem.com/products/bay-985.html
Improvement of PPP was also apparent in a significant decrease of the dermatologic life quality index (DLQI). The median DLQI score dropped from 8.5 at baseline to 2.0 at week 20 (p=0.03. Apremilast was generally well tolerated, and no serious adverse events occurred. Patients with PPP treated with apremilast showed benefit both in objective and subjective disease parameters. Apremilast should be investigated further in this difficult-to-treat skin condition. EudraCT number 2016-005122-11. Patients with PPP treated with apremilast sho
Like
Comment
Share
